Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a 1,5-benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors. Unlike 1,4-benzodiazepines (e.g., diazepam), it has a more favorable profile regarding sedation and cognitive impairment.
## Primary Indications
Adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS). Note: Off-label use includes management of refractory focal or generalized epilepsy and anxiety.
## Adult Dosing
* **Initial:** 10 mg/day orally.
* **Titration:** Increase to 20 mg/day after 1 week. If tolerated and necessary, may increase to a maximum of 40 mg/day in divided doses.
## Pediatric Dosing (≥2 years)
Weight-based dosing applies. Determine total daily dose based on body weight:
* **≤30 kg:** Start at 5 mg/day; titrate to target 10 mg/day (max).
* **>30 kg:** Start at 10 mg/day; titrate to target 20 mg/day (max).
* *Note:* Titrate in 1-week increments. Maximum dose for children >30 kg is 40 mg/day.
## Dose Adjustments
* **Renal Impairment:** No specific adjustment needed; use caution as drug and active metabolites are renally excreted.
* **Hepatic Impairment:** Reduce starting dose by 50% and titrate slowly. Contraindicated in severe impairment (Child-Pugh Class C).
* **CYP2C19 Poor Metabolizers:** Exposure to the active metabolite (N-desmethylclobazam) is increased; start at 50% of the standard dose and titrate cautiously.
## Contraindications
* Known hypersensitivity to clobazam.
* Severe hepatic impairment.
## Adverse Effects
* **Common:** Somnolence, sedation, lethargy, drooling (sialorrhea), pyrexia, constipation, and ataxia.
* **Serious:** Severe dermatological reactions (SJS/TEN), respiratory depression, physical dependence, and suicidal ideation.
## Key Drug Interactions
* **CNS Depressants:** Increased risk of profound sedation/respiratory depression (e.g., opioids, alcohol, other BZDs).
* **CYP2C19 Inhibitors:** (e.g., fluconazole, fluvoxamine) significantly increase levels of the active metabolite.
* **CYP2C19 Inducers:** (e.g., carbamazepine, phenytoin) may decrease efficacy.
* **Hormonal Contraceptives:** May decrease efficacy (clobazam induces CYP3A4).
## Monitoring
* Monitor for signs of respiratory depression and excessive sedation.
* Observe for behavioral changes or mood worsening (suicidality).
* Watch for signs of skin rash (SJS/TEN); discontinue immediately if suspected.
## Clinical Pearls
* **Active Metabolite:** The efficacy of clobazam is largely attributed to its primary metabolite, N-desmethylclobazam, which has a long half-life (up to 40-50 hours).
* **Abrupt Withdrawal:** Must be tapered slowly to avoid status epilepticus or withdrawal seizures.
* **Oral Suspension:** Shake well before use. Use the provided calibrated oral dosing syringe.
* **Compliance:** Monitor for the "tolerance phenomenon," where the anti-seizure effect may diminish over time with chronic use.
***
*Educational Disclaimer: This information is for educational purposes only. Always consult current institutional protocols and official drug monographs (e.g., FDA-approved labeling or Lexicomp/Micromedex) before prescribing or administering medication.*
